Cosibelimab Alternatives Compared
Cosibelimab | Keytruda (pembrolizumab) | Cetuximab |
|
---|
Cosibelimab | Keytruda (pembrolizumab) | Cetuximab |
|
|||||||
---|---|---|---|---|---|---|---|---|---|---|
Prescription only
Prescribed for Squamous Cell Carcinoma. Cosibelimab may also be used for purposes not listed in this medication guide. |
Prescription only
Keytruda is an immunotherapy treatment called a checkpoint inhibitor that helps your immune system fight cancer and is used to treat many different types of cancer in adults and children including... View more |
Prescription only
Prescribed for Head and Neck Cancer, Colorectal Cancer, Squamous Cell Carcinoma, Non Small Cell Lung Cancer, Pancreatic Cancer. Cetuximab may also be used for purposes not listed in this medication guide. View more |
Related suggestions Squamous Cell Carcinoma
|
|||||||
More about Cosibelimab | More about Keytruda (pembrolizumab) | More about Cetuximab | ||||||||
Ratings & Reviews | ||||||||||
Be the first to share your experience with this drug. |
Keytruda has an average rating of 4.9 out of 10 from a total of 252 ratings on Drugs.com. 40% of reviewers reported a positive effect, while 48% reported a negative effect. |
Cetuximab has an average rating of 7.1 out of 10 from a total of 10 ratings on Drugs.com. 50% of reviewers reported a positive effect, while 10% reported a negative effect. |
||||||||
Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||
View all Keytruda side effects |
View all Cetuximab side effects |
|||||||||
Drug Class | ||||||||||
Generic Availability | ||||||||||
N/A |
N/A |
N/A |
||||||||
Pricing and Coupons * Prices are without insurance | ||||||||||
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Keytruda prices |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
||||||||
Dosage Forms | ||||||||||
N/A |
|
N/A |
||||||||
Brand Names | ||||||||||
Unloxcyt |
N/A |
Erbitux | ||||||||
Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||
427.2 hours |
624 hours |
213 hours |
||||||||
CSA Schedule 1 View glossary of CSA terms | ||||||||||
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||
Pregnancy Category | ||||||||||
Summary unavailable. |
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
||||||||
Drug Interactions | ||||||||||
A total of 602 drugs are known to interact with Cosibelimab:
|
A total of 588 drugs are known to interact with Keytruda:
|
A total of 21 drugs are known to interact with Cetuximab:
|
||||||||
Alcohol/Food/Lifestyle Interactions | ||||||||||
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||
Disease Interactions | ||||||||||
No known disease interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||
First Approval Date | ||||||||||
N/A |
N/A |
N/A |
||||||||
WADA Class View classifications | ||||||||||
N/A |
N/A |
N/A |
||||||||
More Information | ||||||||||
Patient Resources | ||||||||||
Professional Resources | ||||||||||
Related Treatment Guide | ||||||||||
|
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.